Ticker

State Street Health Care Select Sector SPDR ETF provides a much lower expense ratio of 0.08% compared to the 0.35% for State Street SPDR S&P Biotech ETF. State Street Health Care Select Sector SPDR ETF offers a higher trailing-12-month dividend yield of 1.6% while State Street SPDR S&P Biotech ETF pays 0.4%.

The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Healthcare systems are facing rising operating pressure, thinner margins, and a harder question about how to manage liquidity across the balance sheet as capital needs become more uncertain. Liquidity is an issue, and an enterprise risk management approach that factors in organizational risks when setting investment strategy can help.

At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery.

I initiate Buy ratings on SPDR S&P Biotech ETF and iShares Biotechnology ETF for 2026–2027, favoring XBI for higher upside. Biotech's rally reflects improving fundamentals: robust M&A, positive clinical data, improved financing, and more quantifiable policy risk, not indiscriminate multiple expansion. MFN drug-pricing risk is narrower than feared, with emerging policies fragmented by payer, product, geography, and…